Differential Immune Reactivity Pattern of SW48 and SW1116 Colorectal Cancer Cell Lines with Colorectal Cancer Patients Sera

Document Type : Original Article


1 Department of Immunology and Allergy, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad; Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Colorectal Research Center, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

3 Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Immunology and Allergy, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Background: Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide. It is also known as the second leading cause of deaths as the early stage detection is not yet available by current methods. So identification of biomarkers can also be functional in early diagnosis and prognosis. Materials and Methods: We examined sera from 60 CRC patients of different stages as a source of auto-antibody as well as two human CRC cell lines with different invasive capacities (SW48 and SW1116) as the source of antigens. The pattern of immune reactivity in immuneblotting tests between mentioned cell lines and CRC patients' sera were evaluated by ImageJ software. Results: The Immune reactivity pattern of two cell lines (SW48 and SW1116) with CRC patients' sera were different in band intensities and the most immune reactivity intensity was observed in SW48 cell lysate with sera from Stage III CRC patients. Conclusion: Due to the humoral immune response, sera from Stage III CRC patients contained autoantibodies that demonstrated higher immune reactivity. Moreover, SW48 cell line with high aggressive behavior reacted to CRC patients' sera with greater intensity compared with less aggressive behavior cell line (SW1116). Therefore, it is required to use other techniques such as two-dimensional electrophoresis and mass spectrometry.


Cheng YL, Zhang GY, Li C, Lin J. Screening for novel protein targets of indomethacin in HCT116 human colon cancer cells using proteomics. Oncol Lett 2013;6:1222-8.  Back to cited text no. 1
Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. Postgrad Med J 2008;84:403-11.  Back to cited text no. 2
Compton CC. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol 2003;16:376-88.  Back to cited text no. 3
Turner RR, Li C, Compton CC. Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res 2007;13 (22 Pt 2):6871s-6.  Back to cited text no. 4
Pionneau C, Canelle L, Bousquet J, Hardouin J, Bigeard J, Caron M. Proteomic analysis of membrane-associated proteins from the breast cancer cell line MCF7. Cancer Genomics Proteomics 2005;2:10.  Back to cited text no. 5
Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588-99.  Back to cited text no. 6
Grandjean M, Dieu M, Raes M, Feron O. A new method combining sequential immunoaffinity depletion and differential in gel electrophoresis to identify autoantibodies as cancer biomarkers. J Immunol Methods 2013;396:23-32.  Back to cited text no. 7
Hamsher C, Smith AM, Dehqanzada ZA, Khoo S, Ponniah S, Peoples GE, et al. Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients. Cancer Immunol Immunother 2007;56:1711-21.  Back to cited text no. 8
Carr KM, Rosenblatt K, Petricoin EF, Liotta LA. Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy. Hum Genomics 2004;1:134-40.  Back to cited text no. 9
Gao H, Zheng Z, Mao Y, Wang W, Qiao Y, Zhou L, et al. Identification of tumor antigens that elicit a humoral immune response in the sera of Chinese esophageal squamous cell carcinoma patients by modified serological proteome analysis. Cancer Lett 2014;344:54-61.  Back to cited text no. 10
Soussi T. p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-88.  Back to cited text no. 11
Greene FL, Sobin LH. The staging of cancer: A retrospective and prospective appraisal. CA Cancer J Clin 2008;58:180-90.  Back to cited text no. 12
Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295-308.  Back to cited text no. 13
Neely D, Campbell W, Davey P, Rodgers C, McCrory D. Colorectal cancer screening: The northern trust experience. Ulster Med J 2013;82:160-3.  Back to cited text no. 14
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-160.  Back to cited text no. 15
Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, et al. Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Crit Rev Oncol Hematol 2013;85:121-35.  Back to cited text no. 16
Nambiar PR, Gupta RR, Misra V. An “Omics” based survey of human colon cancer. Mutat Res 2010;693:3-18.  Back to cited text no. 17
Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J. Anti-p53 autoantibody in colorectal cancer: Prognostic significance in long-term follow-up. Int J Colorectal Dis 2008;23:595-600.  Back to cited text no. 18
Kojima T, Yoshikawa K, Matsui T, Kodera Y, Kojima H. Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer. Mol Med Rep 2009;2:477-80.  Back to cited text no. 19
Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 2004;19:114-20.  Back to cited text no. 20
Roh SA, Choi EY, Cho DH, Jang SJ, Kim SY, Kim YS, et al. Growth and invasion of sporadic colorectal adenocarcinomas in terms of genetic change. J Korean Med Sci 2010;25:353-60.  Back to cited text no. 21
Chen H, Werner S, Tao S, Zörnig I, Brenner H. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett 2014;346:178-87.  Back to cited text no. 22